H19 expression in hepatic metastases from a range of human carcinomas

Journal of Clinical Pathology

Volumn 58, Issue 10, 2005, Pages 1064-1068

  Fellig, Y ^a   Ariel, I ^a   Ohana, P ^b   Schachter, P ^c   Sinelnikov, I ^d   Birman, T ^b   Ayesh, S ^b   Schneider, T ^b   De Groot, N ^b   Czerniak, A ^c   Hochberg, A ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

RNA H19;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LIVER BIOPSY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RNA, NEOPLASM; RNA, UNTRANSLATED; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 26244443510     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2004.023648     Document Type: Article

References (36)

1. Ishac KG, Goodman ZD, Stocker JT, eds. Metastatic tumors. In: Tumors of the liver and intrahepatic bile ducts. Atlas of tumor pathology, 3rd series, fascicle 31. Washington DC: Armed Forces Institute of Pathology, 2001:343-9.
2. Elias D, Maisonnette F, Druet-Cabanac M, et al. An attempt to clarify indications for hepatectomy for hepatic metastases from breast cancer. Am J Surg 2003;185:158-64.
3. Bhattacharya R, Rao S, Kowdley KV. Liver involvement in patients with solid tumors of non-hepatic origin. Clin Liver Dis 2002;6:1033-43.
4. Erce C, Parks RW. Interstitial ablative techniques for hepatic tumors. Br J Surg 2003;90:272-89.
5. Bonetti A. Hepatic artery infusion for hepatic metastases from colorectal cancer [commentary]. Lancet 2003;361:358-9.
6. Adam R, Lucidi V, Bismuth H. Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 2004;84:659-71.
7. Khatri VP, McGahan J. Non-resection approaches for colorectal hepatic metastases. Surg Clin North Am 2004;84:587-606.
8. Allendorf J, Ippagunta N, Emond J. Management of hepatic metastases: new horizons for biologically based therapy. J Surg Res 2004;117:144-53.
9. Ariel I, Miao HQ, Ji XR, et al. Imprinted H19 oncofetal RNA is a candidate tumor marker for hepatocellular carcinoma. Mol Pathol 1998;51:21-5.
10. Ayesh S, Matouk I, Schneider T, et al. Possible physiological role of H19 RNA. Mol Carcinog 2002;35:63-74.
11. Hao Y, Crenshaw T, Moulton T, et al. Tumor-suppressor activity of H19 RNA. Nature 1993;365:764-7.
12. Moulton T, Crenshaw T, Hao Y, et al. Epigenetic lesions at the H19 locus in Wilms' tumor patients. Nat Genet 1994;7:440-7.
13. Taniguchi T, Sullivan MJ, Ogawa O, et al. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. Proc Natl Acad Sci U S A 1995;92:2159-63.
14. van Gurp RJ, Oosterhuis JW, Kalscheuer V, et al. Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. J Natl Cancer Inst 1994;86:1070-5.
15. Verterk AJMH, Ariel I, Dekker MC, et al. Unique expression patterns of H19 in human testicular cancers of different etiology. Oncogene 1997;14:95-107.
16. Ariel I, Lustig O, Oyer CE, et al. Relaxation of imprinting in trophoblastic disease. Gynecol Oncol 1994;53:212-19.
17. Lustig-Yariv O, Schulze E, Komitowski D, et al. The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene? Oncogene 1997;15:169-77.
18. Hibi K, Nakamura H, Hirai A, et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996;56:480-2.
19. Tanos V, Prus D, Ayesh S, et al. Expression of the imprinted H19 oncofetal RNA in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999;85:7-11.
20. Dugimont T, Curgy JJ, Wernert N, et al. The H19 gene is expressed within both epithelial and stromal components of human invasive adenocarcinomas. Biol Cell 1995;85:117-24.
21. Adriaenssens E, Dumont L, Lottin S, et al. H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of P53 and Ki-67 expression. Am J Pathol 1998;153:1597-607.
22. Lottin S, Adriaenssens E, Dupressoir T, et al. Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogen 2002;23:1885-95.
23. Adriaenssens E, Lottin S, Berteaux N, et al. Cross talk between mesenchyme and epithelium increases H19 gene expression during scattering and morphogenesis of epithelial cells. Exp Cell Res 2002;275:215-29.
24. Lynch CA, Tycko B, Bestor TH, et al. Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation. Mol Cancer 2002;1:2.
25. Kanduri C, Kanduri M, Liu L, et al. The kinetics of deregulation of expression by de novo methylation of the H19 imprinting control region in cancer cells. Cancer Res 2002;62:4545-8.
26. Ulaner GA, Vu TH, Li T, et al. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum Mol Genet 2003;12:535-49.
27. Ng A, Tang JP, Goh CHK, et al. Regulation of the H19 imprinting gene expression in human nasopharyngeal carcinoma by methylation. Int J Cancer 2003;104:179-87.
28. Vernucci M, Cerrato F, Pedone PV, et al. Developmentally regulated functions of the H19 differentially methylated domain. Hum Mol Genet 2004;13:353-61.
29. Ariel I, Sughayer M, Fellig Y, et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol Pathol 2000;53:320-3.
30. Tanos V, Ariel I, Prus D, et al. H19 and IGF2 gene expression in human normal, hyperplastic and malignant endometrium. Int J Gynecol Cancer 2004;14:521-5.
31. Kawamoto K, Onodera H, Kan S, et al. Possible paracrine mechanism of insulin-like-growth-factor-2 in the development of liver metastases from colorectal carcinoma. Cancer 1999;85:18-25.
32. Ohana P, Schachter P, Ayesh B, et al. Regulatory sequences of H19 and IGF2 genes in DNA based therapy of colorectal rat hepatic metastases. J Gene Med 2005;7:366-74.
33. Ohana P, Bibi O, Matouk I, et al. Use of H19 regulatory sequences for targeted gene therapy in cancer. Int J Cancer 2002;98:645-50.
34. Ayesh B, Matouk I, Ohana P, et al. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 2003;7:535-41.
35. Ohana P, Gofrit O, Ayesh S, et al. Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer. Gene Ther Mol Biol 2004;8:181-92.
36. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524-36.